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HEART FAILURE AND IMAGING
CASE REPORT: CLINICAL CASE
Cardiac Tamponade Secondary
to COVID-19
Mohammed F. Dabbagh, MD,a Lindsey Aurora, MD,a Penny D’Souza, DO,a Allison J. Weinmann, MBBS,b
Pallavi Bhargava, MD,b Mir B. Basir, DOa
ABSTRACT
A 67-year-old woman presented with upper respiratory symptoms and was diagnosed with coronavirus disease-2019
(COVID-19). She was found to have a large hemorrhagic pericardial effusion with echocardiographic signs of tamponade
and mild left ventricular impairment. Clinical course was complicated by development of takotsubo cardiomyopathy.
She was treated with pericardiocentesis, colchicine, corticosteroids, and hydroxychloroquine, with improvement in
symptoms. (Level of Difficulty: Intermediate.) (J Am Coll Cardiol Case Rep 2020;2:1326–30) © 2020 The Authors.
Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
HISTORY OF PRESENTATION
A 67-year-old woman presented to the emergency
department with cough, mild shortness of breath, and
left shoulder pain. Physical exam and radiographic
imaging of the chest were unremarkable (Figure 1). A
nasopharyngeal swab was positive for severe acute
respiratory syndrome-coronavirus-2 (SARS-CoV-2) by
reverse transcription polymerase chain reaction. She
was discharged home due to mild symptoms.
One week after her initial presentation, she
presented with worsening dyspnea and orthopnea.
Physical exam was pertinent for a blood pressure of
118/82 mm Hg, heart rate of 122 beats/min, respi-
ratory rate of 24 breaths/min, temperature of
36.8C, normal oxygen saturation on room air,
distant heart sounds, and rales at the lung bases
bilaterally.
PAST MEDICAL HISTORY
The patient had a history of nonischemic cardiomy-
opathy with left ventricular ejection fraction (LVEF)
of 15%, diagnosed in 2018 and managed with
guideline-directed medical therapy with improve-
ment in her LVEF to 40%. She had not been not pre-
scribed antiplatelet agents or anticoagulants and had
no history of malignancy or coagulopathy.
DIFFERENTIAL DIAGNOSIS
The differential diagnosis included evolving corona-
virus disease-2019 (COVID-19) pneumonia, acute-on-
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chronic heart failure exacerbation, acute coronary
syndrome, acute pulmonary embolism, myocarditis,
and pericardial disease.
INVESTIGATIONS
Chest x-ray film and computed tomography angiogram
obtained 1 week prior to admission were negative for
pneumonia or pulmonary embolism. Upon represen-
tation to the hospital, chest x-rayfilm demonstrated an
enlarged cardiac silhouette and electrocardiography
(ECG) revealed low voltage in the limb leads with
nonspecific ST-segment changes (Figure 2). Laboratory
testing demonstrated normal levels of high-sensitivity
cardiac troponin I (cTnI) (<18 ng/l; reference range
[RR]: <19 ng/l) and mildly elevated brain natriuretic
peptide (54 pg/ml; RR: <50 pg/ml). Transthoracic
echocardiography (TTE) (Videos 1 and 2) revealed a
large pericardial effusion circumferentially around the
entire heart with signs of early right ventricular dia-
stolic collapse, dilated but collapsing inferior vena
cava, and mitral valve inflow variation of 31% on
pulsed wave Doppler. LVEF was mildly reduced at
40%, with no regional wall motion abnormalities,
similar to TTE 1 year prior.
MANAGEMENT
Given the patient’s worsening symptoms, rapid
expansion of the effusion over 1 week, and
early echocardiographic findings of tamponade, we
elected to proceed with pericardiocentesis. The pa-
tient could not tolerate lying flat because of
severe coughing spells and emesis, so
she underwent elective intubation and was
taken to the cardiac catheterization labora-
tory. Pericardiocentesis yielded 800 ml of
exudative bloody fluid (fluid lactate
dehydrogenase [LDH] 1,697 IU/l, pericardial
fluid LDH/serum LDH >0.6). Fluid cytology
was negative for malignant cells. Acid-fast
bacilli smear was negative, and there was no
growth on cultures. Samples of the fluid
were frozen in an effort to test the presence
of SARS-CoV-2, which is currently not avail-
able in our center. Serum autoimmune work-
up was negative. In the absence of a history
of malignancy, chest trauma, or coagulop-
athy, we suspected the hemorrhagic effusion
to be secondary to COVID-19. Treatment was
started with hydroxychloroquine along with colchi-
cine and glucocorticoids given elevated serum in-
flammatory markers: C-reactive protein (15.9 mg/dl;
RR: <0.5 mg/dl), ferritin (593 ng/ml; RR: 11 to 307 ng/
ml), D-dimer (6.52 mg/ml; RR: <0.68 mg/ml),
and interlukin-6 (8 pg/ml; RR: #5 pg/ml). Serial TTE
demonstrated resolution of the pericardial effusion;
however, the patient was found to have new hypo-
kinesis of the apical and periapical walls
concerning for takotsubo cardiomyopathy (TTC)
(Video 3). This coincided with a rise in cTnI levels to
2,410 (ng/l) and deep T-wave inversions in
precordial leads (V2 to V6) (Figure 3). The patient did
not develop any chest pain or worsening dyspnea. On
the contrary, she reported improvement of
FIGURE 1 Imaging on Initial Presentation
Chest x-ray film (left) and chest computed tomography (right) showing no acute lung disease. Cardiac silhouette appears normal.




cTnI = cardiac troponin I
ECG = electrocardiography
LDH = lactate dehydrogenase
LVEF = left ventricular
ejection fraction
RR = reference range
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FIGURE 2 Chest X-Ray Film and Electrocardiography on Second Presentation
(Left) Chest x-ray film: enlarged cardiac silhouette. (Right) Electrocardiography: normal sinus rhythm with low-voltage QRS complex in limb leads and nonspecific ST-
segment changes in precordial leads.
FIGURE 3 Electrocardiogram After Pericardiocentesis
Electrocardiography: sinus rhythm with deep T-wave inversions in precordial leads V2 to V6.
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dyspnea and was subsequently discharged from the
hospital.
DISCUSSION
SARS-CoV-2 is the novel virus that causes COVID-19
(1). Early studies from Wuhan, China, demonstrated
that patients commonly develop fever, upper respi-
ratory symptoms, and pneumonia (2). As the disease
has spread globally, reports of extrapulmonary man-
ifestations have been frequently identified; however,
pericardial involvement has been rarely reported
(3,4). Here, we report the case of a patient who
developed large symptomatic hemorrhagic pericar-
dial effusion causing cardiac tamponade. There were
no initial signs of cardiac injury or myocardial
involvement, as demonstrated by the absence of cTnI
elevation or wall motion abnormalities on TTE. In
fact, her symptoms were relatively mild until the
development of pericardial effusion.
Viral infections are a common cause of pericarditis
and typically entail a benign clinical course (5). Hem-
orrhagic pericardial effusions have been less
commonly associated with viral infections but have
been reported in coxsackievirus (6). It is hypothesized
that viruses cause pericardial inflammation via direct
cytotoxic effects or via immune-mediated mecha-
nisms (5). COVID-19 has been reported to trigger an
exaggerated systemic inflammatory response in
certain patients; however, details of this response are
not fully understood (3). It is plausible that COVID-19,
similar to other viral infections, elicits an inflamma-
tory response, leading to pericarditis and subsequent
effusion; however, the exact mechanism is unclear.
Hemorrhagic effusions have also been reported in
other inflammatory states such as Dressler’s syn-
drome, which is thought to result from an immune
complex deposition and a subsequent inflammatory
cascade post–myocardial infarction (7,8).
After pericardiocentesis, our patient developed TTC
as evident by TTE, ECG findings, and cTnI elevation.
TTC is a stress-induced cardiomyopathy characterized
by transient apical ballooning with regional wall mo-
tion abnormalities that occur in association with
identifiable emotional or physical stressors including
infections (9). The Mayo Clinic proposed the following
diagnostic criteria for diagnosis of TTC: transient
segmental left ventricular systolic dysfunction,
absence of obstructive coronary artery disease, new
ECG abnormalities or modest cardiac troponin eleva-
tion, and absence of pheochromocytoma or myocar-
ditis (9). Our patient met these diagnostic criteria
clinically and echocardiogram was consistent with
apical ballooning. Cardiac magnetic resonance would
have definitively ruled out the presence of myocar-
ditis. However, it was not performed, as the patient’s
condition continued to improve, and we sought to
further avoid nonessential medical testing to mini-
mize spread of the disease. Acute coronary syndrome
was unlikely, as coronary angiography from 2 years
prior showed no significant coronary artery
disease, and the patient demonstrated no symptoms
of acute coronary syndrome. Although TTC has
been widely reported in the setting of severe
bacterial infections, cases of TTC attributed to viral
infections such as influenza are rare (10). In our case,
troponin elevation and apical hypokinesis occurred
only after intubation and pericardiocentesis; there-
fore, stress from these procedures is also a possible
etiology.
FOLLOW-UP
Our patient received hydroxychloroquine and low-
dose glucocorticoids as per our institutional treat-
ment protocol; however, it is important to note
that currently there are no proven data for efficacy
of this regimen for COVID-19. We also treated our
patient with colchicine, given the elevated in-
flammatory makers. The patient was continued on
guideline-directed medical therapy for nonischemic
cardiomyopathy including beta-blockers, angio-
tensin receptor blockers, and spironolactone.
Repeat TTE prior to discharge demonstrated stable
ejection fraction and resolution of pericardial
effusion.
CONCLUSIONS
We report a rare presentation of COVID-19
infection complicated by a large symptomatic hem-
orrhagic pericardial effusion and development of
TTC.
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APPENDIX For supplemental videos,
please see the online version of this paper.
Dabbagh et al. J A C C : C A S E R E P O R T S , V O L . 2 , N O . 9 , 2 0 2 0
Cardiac Tamponade Secondary to COVID-19 J U L Y 1 5 , 2 0 2 0 : 1 3 2 6 – 3 0
1330
